928 Stock Overview
An investment holding company, provides genetic testing and health data analysis services in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
King International Investment Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.044 |
| 52 Week High | HK$0.12 |
| 52 Week Low | HK$0.04 |
| Beta | 0.22 |
| 1 Month Change | -16.98% |
| 3 Month Change | -46.34% |
| 1 Year Change | -44.30% |
| 3 Year Change | -54.64% |
| 5 Year Change | -79.05% |
| Change since IPO | -100.00% |
Recent News & Updates
Take Care Before Jumping Onto King International Investment Limited (HKG:928) Even Though It's 32% Cheaper
Dec 09
King International Investment Limited (HKG:928) Might Not Be As Mispriced As It Looks After Plunging 26%
Oct 16There's Been No Shortage Of Growth Recently For King International Investment's (HKG:928) Returns On Capital
Oct 15Recent updates
Take Care Before Jumping Onto King International Investment Limited (HKG:928) Even Though It's 32% Cheaper
Dec 09King International Investment Limited (HKG:928) Might Not Be As Mispriced As It Looks After Plunging 26%
Oct 16There's Been No Shortage Of Growth Recently For King International Investment's (HKG:928) Returns On Capital
Oct 15King International Investment Limited (HKG:928) Soars 32% But It's A Story Of Risk Vs Reward
Aug 22King International Investment's (HKG:928) Performance Raises Some Questions
Aug 07King International Investment Limited (HKG:928) Might Not Be As Mispriced As It Looks After Plunging 26%
Dec 21Benign Growth For Life Healthcare Group Limited (HKG:928) Underpins Stock's 43% Plummet
Jul 13Life Healthcare Group (HKG:928) Is Looking To Continue Growing Its Returns On Capital
Oct 28Shareholder Returns
| 928 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -8.3% | 0.2% | 1.5% |
| 1Y | -44.3% | -16.9% | 20.6% |
Return vs Industry: 928 underperformed the Hong Kong Healthcare industry which returned -16.9% over the past year.
Return vs Market: 928 underperformed the Hong Kong Market which returned 20.6% over the past year.
Price Volatility
| 928 volatility | |
|---|---|
| 928 Average Weekly Movement | 13.0% |
| Healthcare Industry Average Movement | 8.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 928 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 928's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 13 | Ming Yan | www.kinginternational.hk |
King International Investment Limited, an investment holding company, provides genetic testing and health data analysis services in the People’s Republic of China and Hong Kong. The company operates through two segments, Healthcare Products and Services Business, and Money Lending Business. The company also engages in money lending activities.
King International Investment Limited Fundamentals Summary
| 928 fundamental statistics | |
|---|---|
| Market cap | HK$81.42m |
| Earnings (TTM) | HK$12.54m |
| Revenue (TTM) | HK$187.44m |
6.5x
P/E Ratio0.4x
P/S RatioIs 928 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 928 income statement (TTM) | |
|---|---|
| Revenue | HK$187.44m |
| Cost of Revenue | HK$160.66m |
| Gross Profit | HK$26.78m |
| Other Expenses | HK$14.24m |
| Earnings | HK$12.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0068 |
| Gross Margin | 14.29% |
| Net Profit Margin | 6.69% |
| Debt/Equity Ratio | 0.9% |
How did 928 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 14:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
King International Investment Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CGS International |
| Ka Kit Po | UOB Kay Hian Research Pte Ltd |